Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Markus Rechsteiner"'
Autor:
Stefanie Hiltbrunner, Lena Cords, Sabrina Kasser, Sandra N. Freiberger, Susanne Kreutzer, Nora C. Toussaint, Linda Grob, Isabelle Opitz, Michael Messerli, Martin Zoche, Alex Soltermann, Markus Rechsteiner, Maries van den Broek, Bernd Bodenmiller, Alessandra Curioni-Fontecedro
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)
Abstract Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell lung cancer (NSCLC), however, some of the patients develop resistance following initial response. Here, we analyze the immune phenotype of matching
Externí odkaz:
https://doaj.org/article/c99e4e76f6b544649dae1c58e4b5b5c4
Autor:
Dilara Akhoundova, Martina Haberecker, Ralph Fritsch, Sylvia Höller, Michael K. Kiessling, Markus Rechsteiner, Jan H. Rüschoff, Alessandra Curioni-Fontecedro
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAnaplastic lymphoma kinase (ALK) rearrangements are known oncogenic drivers in non-small cell lung cancer (NSCLC). Few case reports described the occurrence of such rearrangements in large cell neuroendocrine carcinomas (LCNECs) of the lung
Externí odkaz:
https://doaj.org/article/e591e9021ef5464abbf98b549a36cd75
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
IntroductionThere is no proven therapy for chronic-active antibody-mediated rejection (caABMR), the major cause of late kidney allograft failure. Histological and molecular patterns associated with possible therapy responsiveness are not known.Method
Externí odkaz:
https://doaj.org/article/4d3018aa68e049c989889dd6537c38d2
Publikováno v:
Diagnostic Pathology, Vol 14, Iss 1, Pp 1-14 (2019)
Abstract Background Molecular testing of lung adenocarcinoma for oncogenic driver mutations has become standard in pathology practice. The aim of the study was to analyze the EGFR, KRAS, ALK, RET, ROS1, BRAF, ERBB2, MET and PIK3CA mutational status i
Externí odkaz:
https://doaj.org/article/8dee00dfe5814e768d66c74a45208721
Publikováno v:
Current Problems in Cancer: Case Reports, Vol 1, Iss , Pp 100008- (2020)
Pleomorphic lobular carcinoma (PLC) of the breast with osteoclast like giant cells (OGC) is a very rare variant of lobular carcinoma associated with tumour-associated macrophages (TAM) in the microenvironment. High content of TAM in breast cancer is
Externí odkaz:
https://doaj.org/article/593ad3ab287444eba6f89950ff9f29c7
Autor:
Christian Britschgi, Alfredo Addeo, Markus Rechsteiner, Raphaël Delaloye, Martin Früh, Giulio Metro, Marco Banini, Oliver Gautschi, Sacha I. Rothschild, Peter J. Wild, Giuseppe L. Banna, Alessandra Curioni-Fontecedro
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Introduction: Survival of ALK-rearranged NSCLC patients has dramatically improved by the use of multiple ALK-tyrosine kinase inhibitors (ALK-TKI). However, still little is known about the impact of drug sequencing and clinical features on survival in
Externí odkaz:
https://doaj.org/article/41a98d4dc44d41c88362540a74999f7d
Publikováno v:
PLoS ONE, Vol 14, Iss 8, p e0220691 (2019)
PurposeLung cancer in never smokers is recognized as a distinct molecular, clinicopathologic and epidemiologic entity. The aim of the study was to investigate the molecular profile in Swiss never smokers with lung adenocarcinoma and to correlate the
Externí odkaz:
https://doaj.org/article/d562b71d1e2f4bd682eb4290a8e377d9
Autor:
Peter J. Wild, Kristian Ikenberg, Thomas J. Fuchs, Markus Rechsteiner, Strahil Georgiev, Niklaus Fankhauser, Aurelia Noske, Matthias Roessle, Rosmarie Caduff, Athanassios Dellas, Daniel Fink, Holger Moch, Wilhelm Krek, Ian J. Frew
Publikováno v:
EMBO Molecular Medicine, Vol 4, Iss 8, Pp 808-824 (2012)
Abstract Type II endometrial carcinomas are a highly aggressive group of tumour subtypes that are frequently associated with inactivation of the TP53 tumour suppressor gene. We show that mice with endometrium‐specific deletion of Trp53 initially ex
Externí odkaz:
https://doaj.org/article/70d0e8ef076642e3b05deb723b59fb88
Autor:
Joanna Mangana, Phil F Cheng, Katja Schindler, Benjamin Weide, Ulrike Held, Anna L Frauchiger, Emanuella Romano, Katharina C Kähler, Sima Rozati, Markus Rechsteiner, Holger Moch, Olivier Michielin, Claus Garbe, Axel Hauschild, Christoph Hoeller, Reinhard Dummer, Simone M Goldinger
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0139438 (2015)
Ipilimumab and tremelimumab are human monoclonal antibodies (Abs) against cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab was the first agent to show a statistically significant benefit in overall survival in advanced melanoma patients. Current
Externí odkaz:
https://doaj.org/article/8b3f40cc8c594f6cb05ca30642659a43
Autor:
Niels J Rupp, Peter J Schuffler, Qing Zhong, Florian Falkner, Markus Rechsteiner, Jan H Ruschoff, Christian Fankhauser, Matthias Drach, Remo Largo, Mathias Tremp, Cedric Poyet, Tullio Sulser, Glen Kristiansen, Holger Moch, Joachim Buhmann, Michael Muntener, Peter J Wild
Publikováno v:
Journal of Pathology Informatics, Vol 7, Iss 1, Pp 3-3 (2016)
Background: Intratumoral hypoxia plays an important role with regard to tumor biology and susceptibility to radio. and chemotherapy. For further investigation of hypoxia.related changes, areas of certain hypoxia must be reliably detected within cance
Externí odkaz:
https://doaj.org/article/aa62d964297447b0842298b53727fec8